The highly accurate CardiacSense watch is a medical wearable device cleared by FDA and CE Marked. The CardiacSense watch is an enabler of big data analysis and AI backed healthcare since it provides 24/7/365 monitoring of vital signs. CardiacSense CEO Eldad Shemesh, a 20-year veteran of the Israeli Air Force, founded the company in 2012. The sophisticated, clinically proven CardiacSense cardiac and blood pressure monitoring device was developed by a team of leading physicians with expertise in electrophysiologists and hemodynamic and engineering experts in optics and electronics. The CardiacSense watch is a diagnostic device that helps the physician in taking life saving decisions. CardiacSense solution is a holistic solution that includes the sensors, the user application, the cloud application, and an integration capability to any EMR system. The expert multidisciplinary team at CardiacSense combines years of clinical, technical, and business experience. The level of accuracy of the clinical data that is received from the CardiacSense watch has no equivalent in wearable devices.
Hof HaCarmel Regional Council, Israel
Founded in 2009
11-50 Employees
Working industry
Medical
Type of company
Manufacturer, Educational institution
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
4 Products
Number of services
1 Service
Specialised areas
Biotechnology, Health Care, Health Diagnostics, Medical Device, mHealth, Wearables
CardiacSense offers a wide range of products and services
Product
Products Archive - Cardiac Sense
Go to product >
Product
Products Archive - Cardiac Sense
Go to product >
Service
Services Privacy Policy - CardiacSense
Go to product >
Product
Our Solution - CardiacSense
Go to product >
Product
Technology - CardiacSense
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Israel
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
B
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
B
Grade (A-E)
View details
CardiacSense operates in 1 country around the world
Get an overview of the locations of CardiacSense
Location
Country
State
City
Headquarter
Israel
Haifa District
Hof HaCarmel Regional Council
Some frequent questions that have been asked about CardiacSense
Where is CardiacSense located?
The company headquarter of CardiacSense is located in Hof HaCarmel Regional Council, Haifa District, Israel. It's worth noting, that the company may have more locations
How many employees does CardiacSense approximately have?
As of the latest available information CardiacSense has around 11-50 employees worldwide.
When was CardiacSense founded?
CardiacSense was founded in 2009
In which industries does CardiacSense mainly work?
The company CardiacSense has it's main focus in the industries of Medical
Check out some interesting alternative companies to CardiacSense
CardiacSense Benelux
Bornem, Belgium
51-100 Employees
-
CardiacSense: de slimme, medisch gevalideerde wearable voor ambulante patiëntenmonitoring. CardiacSense: het nieuwe klinisch gevalideerde patiëntbewakingssysteem met CE-markering (MDR). CardiacSense is een medische en gevalideerde wearable met groot gebruiksgemak voor het thuismonitoren van een aantal vitale bio-parameters. Ook al oogt CardiacSense als een polshorloge, het gaat om een heel geavanceerd alles-in-één-apparaat dat continu de vitale waarden van de patiënt registreert. Hoewel CardiacSense de focus legt op het verzamelen van informatie in het kader van cardiologie, kan de wearable met diagnostische meerwaarde breder ingezet worden. Bovendien, CardiacSense laat toe data te laten aansluiten bij controlecentra zoals telezorgdiensten of een verpleegkundigenkamer binnen een bepaalde afdeling in een ziekenhuis of WZC.
Cardiosense
Chicago, United States
1-10 Employees
2020
Cardiosense is building a digital biomarker platform that leverages novel, multi-sensor devices and proprietary algorithms to detect early signs of disease and guide personalized therapy. Built on over a decade of research, our team has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease. Device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data.
Acorai
Helsingborg, Sweden
11-50 Employees
2019
Built on Acorai’s proprietary datasets and data partnerships with world-leading hospitals. The Acorai Heart Monitor has been designed to offer accurate, personalized, and efficient care for heart failure patients. The objective of the Acorai Heart Monitor is to offer accurate estimations of pulmonary pressure to support personalized heart failure treatment. Ongoing clinical validation to provide continuous and actionable information to support decision-making across all stages of heart failure. The Save Sensor System is a first-of-its-kind hardware architecture and machine learning with absolute intracardiac insights in mind. An ongoing clinical study (CAPTURE-HF) aims to confirm if the monitor can deliver actionable information equal to invasive methods. Ensuring that patients are stable prior to discharge reduced reamission rates. EIC invests in companies with innovative, game-changing products, services or business models that could create new markets or disrupt existing ones.
Patch Inc.
-
11-50 Employees
-
We combine human intelligence and artificial intelligence into ultra-light, everyday-wearable patch which provides continuous cardiac monitoring and timely detections and alerts. A single test that provides early detection of cardiac abnormalities may add years to a patient’s life. It is a rapid, seamless test that does not add any burden to the office staff. Just as reliable as the standard echocardiography machines, but without the hassle. Devices like these can save millions of lives every year, and we’re committed to doing everything we can to ensure everyone on earth has access to heart health.
Cardiaccs AS
Oslo, Norway
11-50 Employees
2009
Cardiaccs' smart lead has an integrated sensor for monitoring cardiac function. Cardiaccs' combined sensor and pace lead is placed and removed in the same way as standard temporary pace leads. Cardiaccs' lead has an embedded accelerometer sensor that measures the velocity of each cardiac contraction. Cardiaccs wants to cover the urgent unmet need for better cardiac monitoring to reduce morbidity and mortality in this patient group. Cardiaccs provides technology for measuring myocardial contractility, a vital parameter for monitoring of the cardiac function. Cardiaccs is ISO 13485 certified for the design, development and manufacture of active, non-implantable cardiac monitoring devices and associated software. This is a vital parameter for monitoring the cardiac function. The CS1 research product is suitable for animal trials and is NOT FOR HUMAN USE.
Semacare
Shenzhen, China
11-50 Employees
2014
Semacare focuses on early detection of Cardiovascular diseases through a monitoring and recovering system. The product weighs only 10g and is equivalent to the size of a coin. Founded in January 2019, Shenzhen Semacare Medical Technology Co., Ltd (Semacare) is a medical technology company with a value to lead medical innovation and a mission of “serving mankind through, with and within healthcare”. By applying top technology to the ultimate product design, we aim to develop optimal user experiences, improve the efficiency of medical systems and optimise the value of life information engineering. By leveraging machine learning technology and incorporating it into sleek hardware, Semacare brings ultimate user experiences to both professionals and patients.